+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Estimating the cost-effectiveness of tirofiban for acute coronary syndrome patients managed in a relatively low interventional setting The United Kingdom



Estimating the cost-effectiveness of tirofiban for acute coronary syndrome patients managed in a relatively low interventional setting The United Kingdom



Journal of the American College of Cardiology 41(6 Suppl. A): 524A, March 19




(PDF emailed within 0-6 h: $19.90)

Accession: 034871384

Download citation: RISBibTeXText

DOI: 10.1016/s0735-1097(03)82817-6


Related references

Are glycoprotein IIb/IIIa antagonists cost-effective in acute coronary syndromes Potential impact of tirofiban in the United Kingdom. Journal of the American College of Cardiology 37(2 Suppl. A): 507A, 2001

Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value in Health 11(5): 853-861, 2008

Pin59 - Estimating The Cost-Effectiveness Of Isavuconazole For The Treatment Of Patients With Possible Invasive Aspergillosis In The United Kingdom. Value in Health 21: S230-S231, 2018

The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiology 13(4): 263-274, 2006

Cost-effectiveness analysis of tirofiban use in acute coronary syndromes. Circulation 104(17 Suppl.): II 798, October 23, 2001

The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart 94(6): 717-723, 2007

Should patients with acute coronary syndromes be managed by cardiologist or general physicians? Results from the Prospective Registry of Acute Ischaemic Syndromes in the United Kingdom. Journal of the American College of Cardiology 37(2 Suppl. A): 515A, 2001

Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. American Journal of Cardiovascular Drugs 15(6): 415-427, 2016

Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI. Eurointervention 6(8): 992-996, 2011

Predictors of high-cost managed care patients with acute coronary syndrome. Current Medical Research and Opinion 21(12): 1977-1984, 2005

Pcv85 - Cost-Effectiveness Of Betrixaban Compared With Enoxaparin Or Fondaparinux For Venous Thromboembolism Prophylaxis In Hospitalised Acute Medically Ill Patients In The United Kingdom. Value in Health 21: S106-S107, 2018

Diabetic patients presenting with non-ST-segment elevation acute coronary syndromes, are we treating aggressively enough? Prospective Registry of Acute Ischaemic Syndrome in the United Kingdom. European Heart Journal 21(Abstract Suppl.): 29, August-September, 2000

Long-term follow-up from a national cohort of patients with acute coronary syndrome without ST-elevation Results from the prospective registry of acute ischaemic syndromes in the United Kingdom. European Heart Journal 24(Abstract Suppl.): 154, August-September, 2003

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Journal of Thrombosis and Haemostasis 11(1): 81-91, 2013

Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. International Journal of Cardiology 251: 32, 2018